First Direct Isolation of Stable α-Form Crystals of Mirabegron, a Selective β3–Adrenoceptor Agonist

Authors

  • Vijayavitthal T. Mathad Megafine Pharma (P) Ltd. Plot No. 31 to 35 & 48 to 51/201, Lakhmapur, Tal. Dindori, Dist. Nashik - 422 202, Maharashtra, INDIA.
  • Dattatray G. Deshmukh Department of Process Research and Development, Megafine Pharma (P) Ltd., 201, Lakhmapur, Dindori, Nashik-422 202, Maharashtra, India. & Organic Chemistry Research Center, Department of Chemistry, K. T. H. M College, Nashik-422 002, Maharashtra, India.
  • Mukund N. Bangal Department of Process Research and Development, Megafine Pharma (P) Ltd., 201, Lakhmapur, Dindori, Nashik-422 202, Maharashtra, India.
  • Anil C. Mali Department of Process Research and Development, Megafine Pharma (P) Ltd., 201, Lakhmapur, Dindori, Nashik-422 202, Maharashtra, India.
  • Vijay J. Medhane Organic Chemistry Research Center, Department of Chemistry, K. T. H. M College, Nashik-422 002, Maharashtra, India.

DOI:

https://doi.org/10.17344/acsi.2017.3293

Keywords:

β3-adrenoceptor agonist, Mirabegron, polymorphism, polymorphic transformation

Abstract

An efficient and scalable method for the direct isolation of stable α-form crystals of mirabegron (1) is developed. The developed method negates transformation of metastable β-form crystals into α-form crystals thereby overcome the limitations of reported methods and avoids additional processing steps during its manufacture. The developed method directly provides stable α-form crystals of Mirabegron (1) with yield of around 84 % and purity of >99.77% by HPLC in a single step.

Author Biography

Vijayavitthal T. Mathad, Megafine Pharma (P) Ltd. Plot No. 31 to 35 & 48 to 51/201, Lakhmapur, Tal. Dindori, Dist. Nashik - 422 202, Maharashtra, INDIA.

Senior Vice President,

Research and Development, Megafine Pharma (P) Ltd

Downloads

Published

16.06.2017

Issue

Section

Organic chemistry